Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Common Stock
Apontis Pharma AG
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Common Stock
€8.5m
|
CAGR 3-Years
557%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Common Stock
$18.6m
|
CAGR 3-Years
30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Common Stock
€2.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
Merck KGaA
XETRA:MRK
|
Common Stock
€565m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Common Stock
€53.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Common Stock
€12m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Common Stock?
Common Stock
8.5m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Common Stock amounts to 8.5m EUR.
What is Apontis Pharma AG's Common Stock growth rate?
Common Stock CAGR 3Y
557%
Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for Apontis Pharma AG have been 557% over the past three years .
You don't have any saved screeners yet